Magnesium sulphate intravenously reduces tachycardia side-effects of β2-agonists
Sign Up to like & getrecommendations! Published in 2022 at "Breathe"
DOI: 10.1183/20734735.0015-2022
Abstract: The review by Erumbala et al. [1] correctly proposing magnesium sulphate (MgSO4) as the first intravenous bronchodilator missed vital points of its pharmacological actions. The i.v. drug reduces or eliminates tachycardia and palpitation side-effects of… read more here.
Keywords: magnesium; effects agonists; mgso4; side effects ... See more keywords